InvestorsHub Logo
Post# of 252255
Next 10
Followers 50
Posts 6343
Boards Moderated 0
Alias Born 01/22/2006

Re: Dr_Thorfin post# 210227

Tuesday, 03/28/2017 2:15:25 PM

Tuesday, March 28, 2017 2:15:25 PM

Post# of 252255
OMER:

They actually had a bit more cash as of Q4 but they'll likely burn 10-15m in Q1.

The loan was for 125m they borrowed the first tranche of 80 mil and the other 45 mil is contingent on Omidria sales/market cap. I don't see EU partnership for Omidria bringing much (if anything) and would be disappointing to see them dilute their 721 interest. GPCR's haven't found a partner in years so I am speculating equity offering based on 2 PR's one after the other that aren't new which result in big stock movement.

They said $55M was run rate (based on weekly scripts on one of their calls), if its only that for '17 I'd be very disappointed.

Don't get me wrong I do like the pipeline MASP programs, GPCR's (though they have been slow in developing compounds to target them) particularly targeting GPR174 which is in animal studies.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.